as04

Small moleculeexperimental

Clinical trial activity

11 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
10
Phase 3
8
Phase 4
0

Earliest trial started Nov 1, 2003 (NCT00120848)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2004

    Earliest Phase 3 Sponsor(trial)

2020s

  1. Jan 1, 2022

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • UnclearImmunity, active

    Unclear immunity, active

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • as04

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05561673Phase 1/Phase 2 (Phase 2)Oct 4, 2022GlaxoSmithKline
NCT00572000N/ANov 1, 2007National Institute for Control of Vaccine and Biologicals
NCT00485732Phase 3Jun 1, 2007GlaxoSmithKline
NCT00345878Phase 3Sep 1, 2006GlaxoSmithKline
NCT00344032Phase 3Jul 1, 2006GlaxoSmithKline
NCT00306241Phase 3Mar 1, 2006GlaxoSmithKline
NCT00290277Phase 3Nov 1, 2005GlaxoSmithKline
NCT00169494Phase 3Sep 1, 2004GlaxoSmithKline
NCT00196924Phase 3Jun 1, 2004GlaxoSmithKline
NCT00128661Phase 3Jun 1, 2004GlaxoSmithKline
NCT00120848Phase 2Nov 1, 2003GlaxoSmithKline
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit101022003
National Institute for Control of Vaccine and BiologicalsGovernment1112007
2 organizations
Page 1 / 1